



مركز الكويت لمكافحة السرطان
Kuwait Cancer Control Center

AFatinib (Giotrif®)



Ministry of Health

Name: _____ **File #:** _____ **Ht (cm):** _____
Nationality: _____ **Civil ID:** _____ **Wt (Kg):** _____
Gender/Age: _____ **DOB:** _____ **BSA (m²):** _____

Indication(s): First or subsequent line therapy for advanced stage lung adenocarcinoma with EGFR ex19del or exon 21 (L858R) mutation.

HR +ve breast cancer, Palliative

Central line: Available NA

Allergies: NKA Yes, specify; _____

Standard Protocol:

DRUG	DOSE	ADMINISTRATION
AFatinib	40 mg PO daily	To be given on an empty stomach at least 2 hrs before or 2 hrs after a meal. Don't take a missed dose within 12 hrs from the next dose.
To be given continuously until disease progression or intolerable toxicity.		

Special instructions: For patients who require therapy with a P-glycoprotein/ABCB1 Inhibitors (ex. Amiodarone, Erythromycin, Clarithromycin, Verapamil), reduce afatinib daily dose to 30 mg.
For patients who require chronic therapy with a P-glycoprotein/ABCB1 Inducers (ex. Carbamazepine, Rifampin), increase afatinib daily dose to 50 mg.

Treatment Description:

Cycle	Date	AFatinib	Physician	Consultant
C# __				
C# __				
C# __				
C# __				
C# __				
C# __				
C# __				

Important Notes:

Reported grade 3/4 toxicities: None Hematological Non-Hematological

If yes; Did it indicate hospitalization? Yes No

Did it indicate chemo-delay for ≥ 7 days? Yes No

Did it indicate dose reduction? Yes No

Did it indicate G-CSF support? Yes No